MannKind (MNKD) Competitors $3.92 -0.04 (-0.98%) As of 09:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNKD vs. ALKS, LGND, FOLD, BCRX, CLDX, DVAX, INVA, NVAX, OPK, and GERNShould you be buying MannKind stock or one of its competitors? The main competitors of MannKind include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), and Geron (GERN). These companies are all part of the "biotechnology" industry. MannKind vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Dynavax Technologies Innoviva Novavax OPKO Health Geron Alkermes (NASDAQ:ALKS) and MannKind (NASDAQ:MNKD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends. Is ALKS or MNKD more profitable? Alkermes has a net margin of 23.30% compared to MannKind's net margin of 10.12%. Alkermes' return on equity of 27.52% beat MannKind's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.30% 27.52% 17.98% MannKind 10.12%-32.41%10.85% Do institutionals and insiders hold more shares of ALKS or MNKD? 95.2% of Alkermes shares are owned by institutional investors. Comparatively, 49.6% of MannKind shares are owned by institutional investors. 4.4% of Alkermes shares are owned by insiders. Comparatively, 2.7% of MannKind shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer ALKS or MNKD? Alkermes currently has a consensus target price of $40.92, suggesting a potential upside of 39.48%. MannKind has a consensus target price of $10.14, suggesting a potential upside of 158.68%. Given MannKind's stronger consensus rating and higher probable upside, analysts clearly believe MannKind is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83MannKind 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Which has more risk and volatility, ALKS or MNKD? Alkermes has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, MannKind has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Which has better valuation and earnings, ALKS or MNKD? Alkermes has higher revenue and earnings than MannKind. Alkermes is trading at a lower price-to-earnings ratio than MannKind, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.11$367.07M$2.0914.04MannKind$285.50M4.17$27.59M$0.1039.21 Does the media refer more to ALKS or MNKD? In the previous week, Alkermes had 9 more articles in the media than MannKind. MarketBeat recorded 13 mentions for Alkermes and 4 mentions for MannKind. MannKind's average media sentiment score of 1.33 beat Alkermes' score of 0.86 indicating that MannKind is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAlkermes beats MannKind on 10 of the 17 factors compared between the two stocks. Get MannKind News Delivered to You Automatically Sign up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNKD vs. The Competition Export to ExcelMetricMannKindMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$2.91B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio39.2520.3628.1819.72Price / Sales4.17290.30439.19110.06Price / Cash27.7442.3835.5357.53Price / Book-13.527.768.235.67Net Income$27.59M-$55.11M$3.23B$257.51M7 Day Performance3.18%0.19%-0.61%-0.16%1 Month Performance4.56%10.80%6.63%9.89%1 Year Performance-32.40%-0.68%27.07%15.08% MannKind Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNKDMannKind2.6351 of 5 stars$3.92-1.0%$10.14+158.7%-34.0%$1.19B$285.50M39.25400Positive NewsAnalyst UpgradeGap UpALKSAlkermes4.7942 of 5 stars$29.69-1.9%$40.00+34.7%+18.7%$4.90B$1.51B14.211,800Upcoming EarningsAnalyst ForecastLGNDLigand Pharmaceuticals4.0699 of 5 stars$126.92+4.3%$147.17+16.0%+31.0%$2.45B$181.49M-17.8380FOLDAmicus Therapeutics4.1147 of 5 stars$6.24+2.5%$16.22+160.0%-44.0%$1.92B$543.14M-69.33480Analyst UpgradeBCRXBioCryst Pharmaceuticals4.3835 of 5 stars$8.96+2.3%$16.70+86.4%+12.6%$1.87B$450.71M-34.46530Analyst RevisionCLDXCelldex Therapeutics2.4231 of 5 stars$23.36+2.0%$50.11+114.5%-42.5%$1.55B$7.02M-8.65150News CoveragePositive NewsDVAXDynavax Technologies4.3743 of 5 stars$10.74+1.5%$24.00+123.5%-1.8%$1.29B$294.62M-20.65350INVAInnoviva4.0829 of 5 stars$19.58+4.3%$40.33+106.0%+18.1%$1.23B$358.71M-19.39100Analyst ForecastAnalyst RevisionGap UpNVAXNovavax4.3349 of 5 stars$6.97+1.9%$17.00+143.9%-57.7%$1.13B$1.21B2.631,990OPKOPKO Health4.1876 of 5 stars$1.34-0.7%$2.75+105.2%-5.6%$1.06B$713.10M-19.142,997Positive NewsGERNGeron3.4425 of 5 stars$1.34+1.5%$4.61+244.1%-74.5%$853.47M$116.29M-6.3870 Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives BioCryst Pharmaceuticals Alternatives Celldex Therapeutics Alternatives Dynavax Technologies Alternatives Innoviva Alternatives Novavax Alternatives OPKO Health Alternatives Geron Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNKD) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
